Downloads: 364

Files in This Item:
File Description SizeFormat 
j.bbrc.2015.12.025.pdf1.05 MBAdobe PDFView/Open
Title: The modeling of Alzheimer's disease by the overexpression of mutant Presenilin 1 in human embryonic stem cells
Authors: Honda, Makoto
Minami, Itsunari
Tooi, Norie
Morone, Nobuhiro
Nishioka, Hisae
Uemura, Kengo
Kinoshita, Ayae  kyouindb  KAKEN_id
Heuser, John E.
Nakatsuji, Norio
Aiba, Kazuhiro
Keywords: Alzheimer's disease
Cellular disease model
Human embryonic stem cell
Presenilin 1
Synaptic dysfunction
Issue Date: 15-Jan-2016
Publisher: Academic Press Inc.
Journal title: Biochemical and Biophysical Research Communications
Volume: 469
Start page: 587
End page: 592
Abstract: Cellular disease models are useful tools for Alzheimer's disease (AD) research. Pluripotent stem cells, including human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs), are promising materials for creating cellular models of such diseases. In the present study, we established cellular models of AD in hESCs that overexpressed the mutant Presenilin 1 (PS1) gene with the use of a site-specific gene integration system. The overexpression of PS1 did not affect the undifferentiated status or the neural differentiation ability of the hESCs. We found increases in the ratios of amyloid-β 42 (Aβ42)/Aβ40 and Aβ43/Aβ40. Furthermore, synaptic dysfunction was observed in a cellular model of AD that overexpressed mutant PS1. These results suggest that the AD phenotypes, in particular, the electrophysiological abnormality of the synapses in our AD models might be useful for AD research and drug discovery.
Rights: © 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
URI: http://hdl.handle.net/2433/218506
DOI(Published Version): 10.1016/j.bbrc.2015.12.025
PubMed ID: 26687948
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.